Oxidative Preservatives and Dry Eye
Preservatives are added to ophthalmic preparations to protect against pathogenic microbes and maintain drug potency.
In microbes, they alter cell membranes, inhibit cell metabolism or otherwise interfere with cell function.
Most preservatives have some degree of cytotoxicity in human eyes, particularly with long-term therapy, multiple preserved drugs, and inadequate tear production to wash out the preservative.
On the other hand, oxidative preservatives break down into natural tear components when exposed to light.
OcuPure™ preservative (Advanced Medical Optics), is an oxidative preservative.
A mixture of 80% chlorite, 11% sodium chloride, water and trace electrolytes, it breaks down into sodium and chloride ions, oxygen and water when exposed to light.
OcuPure™ preservative is effective against ocular pathogenic microorganisms and is benign to the eye.
Oxidative Agents in Dry Eye
In one study1, oxidative preservatives were found to be safe and tolerable for patients with mild-to-moderate dry eye (N=62) who were treated four to eight times a day for 4 weeks, thus preparations with low-risk preservatives may benefit patients with dry eye. ■
1. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Therapy. 2001;18:205-215.
|Did You Know?|
|■ Blink® Tears with OcuPure™ preservative is preservative-free in the eye.|
■ COMPLETE® MPS EASY RUB™ Formula is indicated for use with soft contact lenses.
■ Wet eyes can be a sign of dry eye. Wet eyes typically are caused by irritation and rubbing on the cornea.
Tailor-made Vision Correction with iLASIK™
AMO announces the newest advance in corneal refractive surgery: iLASIK™ Laser Vision Correction. The iLASIK™ procedure includes the Advanced CustomVue™ laser vision correction™ FS (femtosecond) laser, and WaveScan™ mapping and guidance.
Three-dimensional mapping, precise measurement and state-of-the art technologies differentiate the iLASIK™ procedure from all other laser procedures.
The iLASIK™ procedure is tailored to the patient and the characterizations of the patient's eyes. The equipment provides better outcomes and superior safety as a result of reduced flap complications.
Clinical Trial Results
At one year after the procedure, more than 95% of all clinical study participants could pass a driving vision test without eyeglasses or contact lenses. Almost three-quarters of participants could see 20/20 without vision-correcting lenses. Four times as many mild-to-moderately nearsighted participants were very satisfied with their night vision after treatment compared to night vision with eyeglasses or contact lenses before treatment.
Ninety-eight percent of mild-to-moderately nearsighted patients could see 20/20 or better; 100% of mild-to-moderately nearsighted patients and 95% of patients with mixed astigmatism could pass a driving vision test without eyeglasses or contact lenses. ■